EloraTZP Hits 23.3% Weight Loss in Phase 2b, but 25% Dropout Rate Raises Flags
The race to build a more potent obesity drug has a new benchmark. A combination therapy called EloraTZP, developed by Eli Lilly, produced 23.3% average body-weight loss over 48 weeks in a mid-stage trial — the strongest result the company has reported for any incretin-based programme to date. The findings were presented at the European … Read more